Friday, 19 December 2014

Parion Sciences, Inc. - Product Pipeline Review - 2014

Parion Sciences, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Parion Sciences, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Parion Sciences, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Parion Sciences, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Parion Sciences, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Parion Sciences, Inc.’s pipeline products

Reasons to buy

- Evaluate Parion Sciences, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Parion Sciences, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Parion Sciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Parion Sciences, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Parion Sciences, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Parion Sciences, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit Parion Sciences, Inc. - Product Pipeline Review - 2014

Planet Biotechnology Inc. - Product Pipeline Review - 2014

Planet Biotechnology Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Planet Biotechnology Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Planet Biotechnology Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Planet Biotechnology Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Planet Biotechnology Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Planet Biotechnology Inc.’s pipeline products

Reasons to buy

- Evaluate Planet Biotechnology Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Planet Biotechnology Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Planet Biotechnology Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Planet Biotechnology Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Planet Biotechnology Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Planet Biotechnology Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
To view the table of contents and know more details please visit Planet Biotechnology Inc. - Product Pipeline Review - 2014

InterMune, Inc. - Product Pipeline Review - 2014

InterMune, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the InterMune, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of InterMune, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of InterMune, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of InterMune, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the InterMune, Inc.’s pipeline products

Reasons to buy

- Evaluate InterMune, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of InterMune, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the InterMune, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of InterMune, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of InterMune, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of InterMune, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit InterMune, Inc. - Product Pipeline Review - 2014

Catalyst Biosciences, Inc. - Product Pipeline Review - 2014

Catalyst Biosciences, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Catalyst Biosciences, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Catalyst Biosciences, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Catalyst Biosciences, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Catalyst Biosciences, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Catalyst Biosciences, Inc.’s pipeline products

Reasons to buy

- Evaluate Catalyst Biosciences, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Catalyst Biosciences, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Catalyst Biosciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Catalyst Biosciences, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Catalyst Biosciences, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Catalyst Biosciences, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit Catalyst Biosciences, Inc. - Product Pipeline Review - 2014

Shanghai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Shanghai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Shanghai Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Shanghai Pharmaceutical Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Shanghai Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Shanghai Pharmaceutical Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Shanghai Pharmaceutical Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate Shanghai Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Shanghai Pharmaceutical Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Shanghai Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Shanghai Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Shanghai Pharmaceutical Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Shanghai Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit Shanghai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Eagle Pharmaceuticals Inc. - Product Pipeline Review - 2014

Eagle Pharmaceuticals Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Eagle Pharmaceuticals Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Eagle Pharmaceuticals Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Eagle Pharmaceuticals Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Eagle Pharmaceuticals Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Eagle Pharmaceuticals Inc.’s pipeline products

Reasons to buy

- Evaluate Eagle Pharmaceuticals Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Eagle Pharmaceuticals Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Eagle Pharmaceuticals Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Eagle Pharmaceuticals Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eagle Pharmaceuticals Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Eagle Pharmaceuticals Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit Eagle Pharmaceuticals Inc. - Product Pipeline Review - 2014

Tonix Pharmaceuticals Holding Corp. - Product Pipeline Review - 2014

Tonix Pharmaceuticals Holding Corp. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Tonix Pharmaceuticals Holding Corp.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Tonix Pharmaceuticals Holding Corp.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Tonix Pharmaceuticals Holding Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Tonix Pharmaceuticals Holding Corp.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Tonix Pharmaceuticals Holding Corp.’s pipeline products

Reasons to buy

- Evaluate Tonix Pharmaceuticals Holding Corp.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Tonix Pharmaceuticals Holding Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Tonix Pharmaceuticals Holding Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Tonix Pharmaceuticals Holding Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tonix Pharmaceuticals Holding Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Tonix Pharmaceuticals Holding Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issuesTo view the table of contents and know more details please visit Tonix Pharmaceuticals Holding Corp. - Product Pipeline Review - 2014